research Baricitinib in the Treatment of Frontal Fibrosing Alopecia: Mid Trial Update
Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.
Search
for
Sort by
Research
120-150 / 1000+ results 
research Most Baricitinib Responders Achieved Full Scalp Hair Regrowth: Findings from Adult and Paediatric BRAVE-AA Trials
Baricitinib effectively regrows scalp hair in most people with severe alopecia areata.
research Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
Upadacitinib effectively treats severe alopecia areata and is safe.
research Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
research Effectiveness of Baricitinib for Nasal, Genital, and Beard Hair Regrowth in Patients with Severe Alopecia Areata: 12-Month Outcomes from a Prospective Observational Study
Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.
research Treatment-Induced Hair Shedding (Dread Shed) Associated with Androgenetic Alopecia Therapies
"Dread shed" is common with minoxidil but less so with other hair loss treatments.
research Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
Baricitinib significantly regrows hair in teens with severe alopecia areata.
research Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata
Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.
research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
research Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
research Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is effective long-term for treating alopecia areata in teens.
research A Systematic Literature Review of Alopecia Areata in Children and Adolescents: Psychosocial Impact
Alopecia areata negatively affects self-esteem, relationships, and academics in young people.
research Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
Baricitinib works better in adolescents than adults for treating severe alopecia areata.
research Primary cutaneous follicle center lymphoma presenting as frontal fibrosing alopecia
Biopsy is crucial for diagnosing unusual hair loss causes like lymphoma.
research Isotretinoin and Hair Loss: A Clinical Perspective and Literature Review
Isotretinoin can cause hair loss, and reducing the dose or using supplements like vitamin D and iron may help.
research A Pilot Investigation of a Gummy-Based Hair Nutraceutical: Preliminary Efficacy Findings
Xtressé™ gummies may help increase hair growth in women, especially in early hair loss stages.
research The Therapeutic Potential of Withania somnifera (Ashwagandha) in Non-Malignant Dermatological Conditions
Ashwagandha may help with skin and hair issues, but more research is needed.
research Adjunctive Dupilumab Therapy in a Partial Responder to Baricitinib for Alopecia Areata
Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.
research Antibody-drug conjugate induced hair loss responds to minoxidil: A case report
Oral minoxidil can help regrow hair lost from antibody-drug conjugate treatment.
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
research Timing of Initial Hair Regrowth and Clinical Trial-Defined Response Following Ritlecitinib Treatment in Patients With Alopecia Areata
Most patients with alopecia areata see significant hair regrowth within 93 days of starting ritlecitinib treatment.
research Real-World Ritlecitinib Treatment of Severe Alopecia Areata (AA) in the US: Patient Characteristics and Physician Satisfaction
Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
research Evaluating the Quality of Social Media Content on Platelet-Rich Plasma for Androgenetic Alopecia and Facial Aesthetics: A Cross-Sectional Study
Social media content on platelet-rich plasma is often poor quality and needs better regulation and more input from doctors.
research Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.
research Alopecia Areata and Vitamin D3 Deficiency: The Potential of Calcipotriol as a Treatment
Calcipotriol's effectiveness for treating alopecia areata is unclear and needs more research.
research Baricitinib Achieved Complete/Near Complete Scalp Coverage in SALT Score ≤20 Responders: 52-Week Findings From BRAVE-AA Trials
Baricitinib significantly regrows hair in severe alopecia areata patients.
research Evidence-Based Data on How Long to Treat to Achieve Treatment Response With Baricitinib in Severe Alopecia Areata
Baricitinib treatment for severe alopecia areata shows significant improvement by 52 weeks, especially in very severe cases.
research Characterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy with Baricitinib 4-mg: Results From BRAVE-AA1 and -AA2 Trials
Some patients on Baricitinib for alopecia areata lost response, often linked to longer and more severe initial conditions.
research Understanding the Experience of Healthcare Access and Health-Related Impacts among Individuals with Alopecia Areata
People with alopecia areata face different healthcare access and experiences based on their race and ethnicity.
research A Novel Nutraceutical Gummy for Hair Regrowth in Women: A Case Series
The gummy improved hair growth and reduced shedding in women.